Advances in fluorescent probe design and imaging applications for Alzheimer's disease biomarker
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Alzheimer's disease research and treatments · Sulfur Compounds in Biology · Molecular Sensors and Ion Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Hydrogen Sulfide in Pharmacotherapy, Beyond the Hydrogen Sulfide-Donors10.3390/biom10020323 ↗
2. Thalamic pathology and memory loss in early Alzheimer's disease: moving the focus from the medial temporal lobe to Papez circuit10.1093/brain/aww083 ↗
3. Presymptomatic Alzheimer's disease in the Dominantly Inherited Alzheimer's Network (DIAN)
4. In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease10.1093/brain/aws239 ↗
5. Remembering in Alzheimer's disease: the “Bobs” at the turn of the new century10.1016/j.jalz.2005.06.021 ↗
6. Rare CODING MUTATIONS associated with alzheimer disease and other dementias
7. Biochemically-defined pools of amyloid-β in sporadic Alzheimer's disease: correlation with amyloid PET10.1093/brain/awx057 ↗
8. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease10.1093/brain/awx171 ↗
9. Optimizing the selection of cortical thickness regions to predict mci progression to AD dementia: application to rosas and adni
10. Cannabidiol for neuropsychiatric symptoms in Alzheimer's dementia10.1002/alz.067170 ↗
11. Patient and caregiver views on participating in clinical trials for behavior problems with Alzheimer's disease10.1002/alz.080211 ↗
12. Transcranial pulse stimulation (TPS) as a method for treating the central nervous system of patients with Alzheimer's disease10.1002/alz.071064 ↗
13. Understanding comorbid metabolic dysfunctions in Alzheimer's disease using the AD-BXDs10.1002/alz.064808 ↗
14. Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease10.1002/alz.046004 ↗
15. MRI-assessed locus coeruleus integrity is heritable and associated with multiple cognitive domains, mild cognitive impairment, and daytime dysfunction10.1002/alz.12261 ↗
16. HMGB1-Mediated senescence and brain inflammation contributes to cognitive dysfunctions10.1002/alz.068747 ↗
17. The extent of lead-induced pathogenesis of alzheimer's disease, synaptic dysfunction and cognitive impairment in rats10.1002/alz.082971 ↗
18. Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction10.1038/s41591-018-0297-y ↗
19. Tributyrin oral administration significantly attenuates the loss of intestinal butyrate-producing bacteria and the ensuing cognitive dysfunction associated with Alzheimer's Disease pathogenesis in 3xTg-AD mice10.1002/alz.076023 ↗
20. Loss of F-actin in synaptosomes correlates with cognitive dysfunction (braak staging, B-amyloid load and tangle load) in patients with mci and AD
21. Taddei · Alzheimer's Dement · 2023 · 1910.1002/alz.078600 ↗
22. Early diagnosis for Alzheimer's disease: clinical criteria and use of biomarkers10.1002/alz.037509 ↗
23. Studying ABI3 variant immune contributions to Alzheimer's disease in a transgenic mouse model10.1002/alz.047365 ↗
24. Enhanced activity of Alzheimer disease-associated variant of protein kinase Cα drives cognitive decline in a mouse model10.1038/s41467-022-34679-7 ↗
25. Neuroprotective effect of PERILLYL alcohol in experimental sporadic AD10.1002/alz.077698 ↗
26. Risk prediction of Alzheimer's dementia in mild cognitive impairment – impact of AD biomarker disclosure on quality of life, mental health and risk knowledge: the PreDADQoL study10.1002/alz.067305 ↗
27. Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification10.1186/s40035-024-00442-9 ↗
28. Neuroprotective effect of paliperidone in lps induced animal model of AD10.1002/alz.077669 ↗
29. Evolution of hippocampal atrophy and episodic memory impairment along the Alzheimer disease biological continuum through the AD-CSF-Index
30. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment10.1016/j.jalz.2012.09.017 ↗
31. Memory impairments in Tg19959 and APP/PS1 AD model mice are alleviated by eEF2K inhibitor A-484954
32. Memory impairments and synaptic deficits in Tg19959 and APP/PS1 AD model mice are alleviated by eEF2K inhibitor A-484954
33. Optogenetic activation of blp to ventral CA1 inputs improves anxiety and memory deficit in AD mice
34. Circulating cell-free mitochondrial DNA (ccf-mtDNA) and memory in mild cognitive impairment (MCI) and Alzheimer's disease (AD)10.1002/alz.071912 ↗
35. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects10.1212/01.WNL.0000151959.64379.1B ↗
36. Vulnerability of the cholinergic basal forebrain to AD versus ftld-tdp pathology in primary progressive aphasia
37. Don't forget primary progressive aphasia for anti-amyloid drugs: an estimation of eligible patients from the Lausanne memory center registry10.1002/alz.13092 ↗
38. Progressive aphasia secondary to Alzheimer disease vs FTLD pathology10.1212/01.wnl.0000287073.12737.35 ↗
39. Functional decline in the aphasic variant of Alzheimer's disease10.1002/alz.12331 ↗
40. Aphasic variant of Alzheimer disease Clinical, anatomic, and genetic features10.1212/WNL.0000000000003165 ↗
41. Impaired affective prosody in AD Relationship to aphasic deficits and emotional behaviors10.1212/WNL.57.8.1474 ↗
42. Shared neural correlates of limb apraxia in early stages of Alzheimer's dementia and behavioural variant frontotemporal dementia10.1016/j.cortex.2016.08.009 ↗
43. Case 11-2020: a 37-Year-Old man with facial droop, dysarthria, and kidney failure10.1056/NEJMcpc1916252 ↗
44. Hyperconnectivity associated with Anosognosia accelerating clinical progression in amnestic mild cognitive impairment10.1021/acschemneuro.1c00595 ↗
45. Evolution of anosognosia in Alzheimer'S disease and its relationship to amyloid10.1002/ana.25649 ↗
46. Pathogenesis of miR-155 on nonmodifiable and modifiable risk factors in Alzheimer's disease10.1186/s13195-023-01264-z ↗
47. Cognitive and anatomical correlates of anosognosia in amnestic mild cognitive impairment and early-stage Alzheimer's disease10.1017/S1041610216001812 ↗
48. Resting-state networks and anosognosia in Alzheimer's disease10.3389/fnagi.2024.1415994 ↗
49. Altered interplay among large-scale brain functional networks modulates multi-domain Anosognosia in early alzheimer's disease10.3389/fnagi.2021.781465 ↗
50. Visuospatial working memory is severely impaired in Bálint syndrome patients10.1016/j.cortex.2015.05.023 ↗
51. Perceiving collision impacts in alzheimer's disease: the effect of retinal eccentricity on optic flow deficits10.3389/fnagi.2015.00218 ↗
52. Visuospatial impairment in Parkinson's disease10.1212/WNL.41.3.365 ↗
53. Oxidative stress: the core pathogenesis and mechanism of Alzheimer's disease10.1016/j.arr.2022.101619 ↗
54. Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer's disease10.1186/s13024-024-00702-2 ↗
55. Elevated oxidative stress and inflammatory levels are associated with plasma AD biomarkers in middle-age10.1002/alz.059828 ↗
56. Oxidative stress biomarkers in individuals with Down syndrome: implications to the pathogeny of Alzheimer's disease10.1002/alz.054260 ↗
57. Analysis of genetic variants related to oxidative stress in patients with Alzheimer's disease10.1002/alz.062766 ↗
58. Investigating the role of neuronal oxidative stress in early Alzheimer's disease pathology10.1002/alz.041171 ↗
59. NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer's diseases10.1016/j.redox.2021.101947 ↗
60. Targeting free radicals in oxidative stress-related human diseases10.1016/j.tips.2017.04.005 ↗
61. Imine-Linked covalent organic framework modulates oxidative stress in alzheimer's disease10.1021/acsami.2c19839 ↗
62. Photobiomodulation in human neuroblastoma under oxidative stress10.1002/alz.063129 ↗
63. Cornuside ameliorates cognitive impairments in scopolamine induced AD mice: involvement of neurotransmitter and oxidative stress10.1016/j.jep.2022.115252 ↗
64. Implicating XIST in sex-biased autoimmunity10.1038/s41588-024-01699-6 ↗
65. The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis10.1002/alz.12683 ↗
66. The Association of Tau with mitochondrial dysfunction in Alzheimer's Disease
67. Fišar · Antioxidants-Basel · 2024 · 13 · 19110.3390/antiox13020191 ↗
68. SA34 - mitochondrial dysfunction in ALZHEIMER'S disease10.1016/j.euroneuro.2017.08.106 ↗
69. Human fibroblasts from sporadic Alzheimer's disease (AD) patients show mitochondrial alterations and lysosome dysfunction10.1016/j.freeradbiomed.2024.07.013 ↗
70. VDAC1, mitochondrial dysfunction, and alzheimer's disease10.1016/j.phrs.2018.03.010 ↗
71. Nano-brake halts mitochondrial dysfunction Cascade to alleviate neuropathology and rescue alzheimer's cognitive deficits10.1002/advs.202204596 ↗
72. Syringaresinol suppresses excitatory synaptic transmission and picrotoxin-induced epileptic activity in the hippocampus through presynaptic mechanisms10.1016/j.neuropharm.2017.12.014 ↗
73. The discovery and characterization of targeted perikaryal-specific brain lesions with excitotoxins
74. Cholinergic submucosal neurons display increased excitability following in vivo cholera toxin exposure in mouse ileum10.3389/fphys.2018.00260 ↗
75. Excitotoxins, mitochondrial and redox disturbances in multiple sclerosis10.3390/ijms18020353 ↗
76. Microtubule-dependent processes precede pathological calcium influx in excitotoxin-induced axon degeneration10.1111/jnc.14909 ↗
77. Effects of repetitive mild traumatic brain injury on neural immune signaling and Alzheimer's disease-like pathology
78. Similarity and differences in inflammation-related characteristics of the peripheral immune System of patients with parkinson's and alzheimer's diseases10.3390/ijms18122633 ↗
79. Early inflammation and immune response mRNAs in the brain of AD11 anti-NGF mice
80. A non-inflammatory immune response after DNA Aβ 1-42 immunization reduced senile plaques and neurofibrillary tangles in brains from 3XTG-AD mice
81. Innate immune cell death in neuroinflammation and alzheimer's disease10.3390/cells11121885 ↗
82. Neuroinflammation in Alzheimer's disease: insights from peripheral immune cells10.1186/s12979-024-00445-0 ↗
83. A comprehensive machine-learning model applied to Magnetic Resonance Imaging (MRI) to predict Alzheimer's Disease (AD) in older subjects10.3390/jcm9072146 ↗
84. Magnetic Resonance Imaging (MRI): basics for the gynecologist10.1016/j.jmig.2021.09.351 ↗
85. Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment10.1007/s00415-018-9016-3 ↗
86. Associations between texture of T1-weighted magnetic resonance imaging and radiographic pathologies in Alzheimer's disease10.1111/ene.14609 ↗
87. Prediction of alzheimer's disease progression based on magnetic resonance imaging10.1021/acschemneuro.1c00472 ↗
88. Aortic healing following type B Aortic Dissection (AD): Temporal morphologic changes on Computed Tomography (CT)10.1016/j.jvs.2017.03.132 ↗
89. Computed tomography density and Aβ deposition of intraorbital optic nerve May assist in diagnosing mild cognitive impairment and alzheimer's disease: a 18F-Flutemetamol positron emission Tomography/Computed tomography Study10.3389/fnagi.2022.836568 ↗
90. The value of whole-brain CT perfusion imaging and CT angiography using a 320-slice CT scanner in the diagnosis of MCI and AD patients10.1007/s00330-017-4865-1 ↗
91. Imaging neurotransmitters with small-molecule fluorescent probes10.1002/anie.202406401 ↗
92. Color-Switchable Nanosilicon Fluorescent probes10.1021/acsnano.2c07443 ↗
93. A fluorescent membrane tension probe10.1038/s41557-018-0127-3 ↗
94. Fluorescent probes for the detection of disease-associated biomarkers10.1016/j.scib.2022.01.014 ↗
95. Huang · Chem Soc Rev · 2021 · 50 · 772510.1039/D0CS01340D ↗
96. Supramolecular fluorescent hydrogelators as bio-imaging probes10.1039/C8MH01130C ↗
97. Fluorescent probes for nanoscopic imaging of Mitochondria10.1016/j.chempr.2019.03.011 ↗
98. Accounts. Fluorescent probes for the visualization of cell viability10.1021/acs.accounts.9b00289 ↗
99. The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer's disease10.1007/s00401-020-02198-8 ↗
100. The coarse-grained plaque is an Aβ plaque-type in APOE Ɛ4+ Alzheimer's disease that is associated with astrogliosis and p-tau burden10.1002/alz.067670 ↗